Immunic Approves Equity Plan Amendment at Annual Meeting

Immunic ( (IMUX) ) has shared an update.

On June 4, 2025, Immunic, Inc. held its annual stockholders’ meeting where key decisions were made, including the approval of an amendment to the 2019 Omnibus Equity Incentive Plan, increasing authorized shares by 7 million to a total of 26,448,871. Additionally, Dr. Jörg Neermann, Ms. Tamar Howson, and Mr. Barclay Phillips were elected as Class II Directors, and Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are poised to impact Immunic’s operational strategies and governance structure moving forward.

The most recent analyst rating on (IMUX) stock is a Buy with a $1.20 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.

Spark’s Take on IMUX Stock

According to Spark, TipRanks’ AI Analyst, IMUX is a Underperform.

Immunic’s overall stock score is primarily impacted by its challenging financial performance, marked by high R&D costs without corresponding revenue. Technical analysis shows moderate short-term bullish signals, but long-term valuation remains unattractive due to negative earnings and lack of dividends. The company’s ability to improve its financial position relies heavily on successful product commercialization or securing additional funding.

To see Spark’s full report on IMUX stock, click here.

More about Immunic

Immunic, Inc. operates in the biotechnology industry, focusing on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases.

Average Trading Volume: 1,065,450

Technical Sentiment Signal: Sell

Current Market Cap: $67.07M

See more insights into IMUX stock on TipRanks’ Stock Analysis page.